Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
- MB-106: CR rate of 38% (N=8) with durability up to 8 months - Builds on CRi rate of 60% in MB-105 monotherapy AML trial last cohort (N=5) - MB-107: Phase 1B median extended overall survival of 11 months for heavily pre-treated subjects (N=15) - MB-107 Phase 1B/2...
Moleculin Reports Third Quarter 2023 Financial Results
- Ends Quarter with $24.6 million in Cash with Runway Estimated into Third Quarter of 2024 - Third quarter marked by additional positive clinical data from Annamycin lead development programs - Growing body of Annamycin efficacy and safety clinical data expected to...
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
HOUSTON, Nov. 7, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will...
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
- Poster Presented at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting - Annamycin continues to be 100% non-cardiotoxic - Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma HOUSTON, Nov. 6,...
Moleculin to Participate in the Virtual Investor Ask the CEO Conference
Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 24th at 12:00 PM ET HOUSTON, Oct. 11, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical...
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
- Phase 1B portion of Phase 1B/2 study demonstrated preliminary CR/CRi rate of 33% (n=6) - Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of AML HOUSTON, Oct. 2, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the...
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
- Data readouts expected before year end - Previously reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of STS lung mets with >60% of the subjects exhibiting stable disease after two cycles of treatment -...
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
- Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company's Annamycin clinical trials - Next generation anthracycline, Annamycin, has demonstrated both safety and promising early activity...
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
HOUSTON, Sept. 14, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced its abstract...
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Sept. 5, 2023 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Walter...